HealthTech Valuations in Europe 2025 - Digital Therapeutics (DTx) Specific Trends and Multiples

General HealthTech Valuations in Europe (2025)

The European healthtech M&A market has been active in 2025, with a notable increase in deal volume and value. While the overall trend is positive, valuations are becoming more selective, with a strong emphasis on profitability, proven business models, and strategic value.

Average Revenue Multiples (EV/Revenue): The average revenue multiple for general healthtech companies in Europe is typically in the range of 4x-6x. Some reports from Q1 2025 cited a more precise average of 4.8x.

Average EBITDA Multiples (EV/EBITDA): For healthtech companies with positive earnings, the enterprise value to EBITDA multiple is generally observed between 10x-14x, a slight increase from the 2024 range.

Digital Therapeutics (DTx) Specific Trends and Multiples

Digital therapeutics, as a specialized and high-growth sub-sector of healthtech, can command premium valuations, especially for companies with certain characteristics.

Premium for AI and Innovation: Companies with proprietary AI solutions, robust data platforms, or those adjacent to the biotech sector are attracting heightened interest. These firms can see multiples rise to 6x-8x revenueor even higher, well above the sector average. This premium reflects a buyer's willingness to invest in technology that delivers measurable cost savings and improved patient outcomes.

Focus on Clinical Validation and Reimbursement: The market is maturing, and investors are demanding more than just a good idea. They are looking for companies with:

Clinically proven datasets.

Clear regulatory and reimbursement pathways.

Defensible business models, often linked to value-based care.

Shift to Value-Based Care: Digital therapeutics that enable a shift from fee-for-service to value-based care are particularly attractive. Solutions for chronic disease management and population health analytics are gaining traction with payers and providers, and these companies can see multiples climb to 5.5x-7x revenue.

M&A Activity and "Selective Scale": The first half of 2025 has seen a trend of "selective scale" in the digital health sector. While overall funding has declined, the average deal size for late-stage financings has increased. This signals a global reallocation of capital towards more substantial, proven investments rather than a broad, speculative approach. M&A activity is largely driven by consolidation, with larger entities acquiring smaller, specialized firms to broaden their portfolios.

Market Context and Drivers

Several factors are shaping the valuation landscape in 2025:

AI Integration: Artificial intelligence is a primary driver of valuation, as firms with proprietary AI algorithms for diagnostics, drug discovery, or patient care are seeing heightened interest.

Regulatory Clarity: In Europe, regulatory bodies like the EMA are refining frameworks for digital health tools, which boosts investor confidence and can lead to a lift in multiples for compliant firms.

Chronic Disease Management: The rising prevalence of chronic conditions like diabetes and obesity is creating a strong demand for effective digital health interventions, making this a key growth area.

Private Equity Interest: Private equity firms are increasingly active in the European healthtech space, competing with strategic buyers for attractive assets. This is driving up competition and, in some cases, valuations for high-quality companies.

To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email [email protected]